Skip to main content

Day: May 12, 2020

Nova LifeStyle, Inc. Announces Financial and Operating Results For Fiscal 2019

LOS ANGELES, May 12, 2020 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced financial results for fiscal year ended December 31, 2019.Key Financial Highlights:Revenues for the year ended December 31, 2019 were $21.9 million, as compared to $81.1 million in the fiscal year for 2018.Gross Profit was $1.2 million in 2019, as compared to $15.3 million in 2018.Net loss from continuing operations was $6.1 million in 2019, as compared to a $5.2 million profit in 2018.The key financial highlights exclude Bright Swallow International Group Limited.  As of December 31, 2019, operations of Bright Swallow were reported as discontinued operations in the consolidated financial statements for all periods presented. Accordingly, assets, liabilities, revenues, expenses and cash flows related...

Continue reading

Iconix Reports Financial Results for the First Quarter 2020

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) —Total revenue of $28.0 million compared to $35.9 million in the prior year quarter.GAAP Operating Loss – $4.9 million as compared to income of $18.4 million in the prior year quarter.Adjusted EBITDA of $11.6 million, compared to $18.4 million in the prior year quarter.Signed 41 license deals during 2020, representing $24 million of aggregate guaranteed minimum royalties over the life of these contracts.Improved cost structure, decreasing SG&A cost 5% from prior year quarter.Iconix Brand Group, Inc. (Nasdaq: ICON) (“Iconix” or the “Company”) today reported financial results for the first quarter ended March 31, 2020.Bob Galvin, CEO commented, “While we began 2020 focused on the continued stabilization of our business and our operational cost structure, the...

Continue reading

Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response

Repotrectinib Granted Fast Track Designation in ROS1-Positive Advanced Non-Small Cell Lung Cancer Patients Not Previously Treated with a ROS1 Tyrosine Kinase Inhibitor First Quarter Progress with Site Activations and Patient Enrollment Across Four Ongoing Clinical Trials including Registrational Phase 2 TRIDENT-1 Study with Approximately 50 Percent of Clinical Trial Sites Now Activated Preclinical Data for TPX-0046 Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting on May 29 Preclinical Data Highlighting Repotrectinib Combinations and ALK-Inhibitor Candidate TPX-0131 to be Presented at American Association for Cancer Research (AACR) Virtual Annual Meeting, June 22-24 Cash, Cash Equivalents, and Marketable Securities of $381 Million Expected to Fund Current Operations into 2022SAN DIEGO,...

Continue reading

Osisko Declares Second Quarter 2020 Dividend

MONTREAL, May 12, 2020 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (OR: TSX & NYSE) is pleased to announce a second quarter 2020 dividend of C$0.05 per common share. The dividend will be paid on July 15, 2020 to shareholders of record as of the close of business on June 30, 2020.For shareholders residing in the United States, the U.S. dollar equivalent will be determined based on the daily rate published by the Bank of Canada on June 30, 2020. This dividend is an “eligible dividend” as defined in the Income Tax Act (Canada).The Company also wishes to remind its shareholders that it has implemented a dividend reinvestment plan (the “Plan”). Shareholders who are residents of Canada and the United States may elect to participate in the Plan in connection with the dividend to be paid on...

Continue reading

Osisko déclare un dividende pour le deuxième trimestre de 2020

MONTREAL, 12 mai 2020 (GLOBE NEWSWIRE) — Redevances Aurifères Osisko Ltée (la « Société » ou « Osisko ») (TSX et NYSE : OR) a le plaisir d’annoncer un dividende pour le deuxième trimestre de 2020 de 0,05 $ CAD par action ordinaire. Le dividende sera payé le 15 juillet 2020 aux actionnaires inscrits aux registres en date du 30 juin 2020 à la fermeture des bureaux.Pour les actionnaires résidant aux États-Unis, le dollar américain équivalent sera déterminé en fonction du taux de change journalier publié par la Banque du Canada le 30 juin 2020. Ce versement de dividende est considéré comme un dividende déterminé, tel que défini par la Loi de l’impôt sur le revenu (Canada).La Société souhaite aussi rappeler à ses actionnaires inscrits au Canada et aux États-Unis qu’elle a mis en place un régime de réinvestissement des dividendes...

Continue reading

Inuvo Announces Filing of the Audited Financial Results for the Fourth Quarter and Full Year Ending December 31, 2019

LITTLE ROCK, Ark., May 12, 2020 (GLOBE NEWSWIRE) — Inuvo, Inc. (NYSE American: INUV), a leading provider of marketing technology, powered by IntentKey™ artificial intelligence that serves brands and agencies, today announced it filed with the Securities and Exchange Commission its audited financial results for the fourth quarter and full year period ending December 31, 2019. On March 25, 2020, we announced preliminary unaudited financial results for the fourth quarter and full year period ending December 31, 2019 and that we were taking advantage of regulatory relief provided by the Securities and Exchange Commission and taking an additional 45 days to file our Form 10-K and audited 2019 financial statements. Fourth Quarter and Full Year Ended December 31, 2019:Net revenue for the 2019 fourth quarter totaled $18.2 million as compared...

Continue reading

Calian Reports Record Second Quarter Results

OTTAWA, May 12, 2020 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX:CGY) today released its quarterly results for the three-month period ended March 31, 2020.Second quarter 2020 highlights:      • Record quarterly revenue for the seventh consecutive quarter      • Quarterly revenue at $104.5 million, exceeding $100 million for the first time        • Adjusted EBITDA(1) at $10.2 million       • 74th consecutive profitable quarter      • New contract signings of $140 million      • Dividend of $0.28 per shareAdjusted EBITDA(1) for the second quarter was $10.2 million, an increase of 55% from $6.6 million in the same quarter of the previous year. Net profit for the second quarter was $5.3 million, an increase of 36% from $3.9 million in the same period of the prior year. Adjusted net profit,(1) which excludes non-cash items related to recent...

Continue reading

Sun BioPharma, Inc. Provides a Business Update and Reports Q1 2020 Financial Results

MINNEAPOLIS, May 12, 2020 (GLOBE NEWSWIRE) — Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter ended March 31, 2020.First-Line Combination Pancreatic Cancer moves into expansion phase prior to COVID-19 pauseDuring the first quarter of 2020, the Company completed enrollment in an added fourth cohort that was intended to study a dose schedule more conveniently aligned with the standard gemcitabine and nab-paclitaxel regimen, and immediately began enrollment of subjects in the expansion phase of this clinical trial. This trial, a Phase 1a/1b combination of SBP-101 with gemcitabine and nab-paclitaxel in patients previously untreated for metastatic...

Continue reading

Osisko Reports First Quarter 2020 Results

MONTRÉAL, May 12, 2020 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (OR: TSX & NYSE) today announced its consolidated financial results for the first quarter of 2020.HighlightsCash flows from operating activities of $23.8 million (Q1 2019 – $24.8 million); $27.9 million before changes in non-cash working capital items (Q1 2019 – $22.6 million), an increase of 23%;Revenues from royalties and streams of $37.8 million (Q1 2019 – $33.5 million), an increase of 13%;Earned 18,159 gold equivalent ounces1 (“GEOs”) (Q1 2019 – 19,753 GEOs);Cash on hand of $158.3 million and up to $400.0 million further available under the credit facility as at March 31, 2020, excluding the $85.0 million equity financing completed on April 1, 2020;Closed a non-brokered private placement of $85.0 million with Investissement...

Continue reading

Osisko publie ses résultats pour le premier trimestre de 2020

MONTRÉAL, 12 mai 2020 (GLOBE NEWSWIRE) — Redevances Aurifères Osisko Ltée (la « Société » ou « Osisko ») (TSX et NYSE : OR) annonce aujourd’hui ses résultats financiers consolidés pour le premier trimestre de 2020.Faits saillantsFlux de trésorerie générés par les activités d’exploitation de 23,8 millions de dollars (T1 2019 – 24,8 millions de dollars); 27,9 millions de dollars avant la variation des éléments hors caisse (T1 2019 – 22,6 millions de dollars), une augmentation de 23 %;Produits provenant des redevances et des flux de 37,8 millions de dollars (T1 2019 – 33,5 millions de dollars), une augmentation de 13 %;18 159 onces d’équivalent d’or1 gagnées (T1 2019 – 19 753 onces d’équivalent d’or);158,3 millions de dollars en trésorerie et un montant disponible supplémentaire pouvant atteindre 400 millions de dollars sur la facilité...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.